FDA Requires Additional Data For Seroquel XR Supplemental New Drug Application
Featured ArticleMain Category: Depression
Also Included In: Regulatory Affairs / Drug Approvals; Pharma Industry / Biotech Industry; Psychology / Psychiatry
Article Date: 26 Dec 2008 - 8:00 PDT
| Patient / Public: | ![]() |
3.5 (2 votes) |
| Healthcare Prof: | ![]() |
3.67 (3 votes) |
The U.S. FDA (Food and Drug Administration) has asked AstraZeneca, the makers of Seroquel XR (quetiapine fumarate), for additional information for its extended release tablets for the treatment of MDD (Major Depressive Disorder) in adult patients.
The FDA's CRL (Complete Response Letter) was sent to AstraZeneca on 24th December. AstraZeneca says it is evaluating the contents of the letter and the proposed labeling revisions. The company says it will resume discussions with the FDA and will "provide a response to the agency in due course".
SEROQUEL XR, a once-daily, extended release formulation of SEROQUEL (quetiapine fumarate), was approved in the United States in 2007 for the acute and maintenance treatment of schizophrenia in adult patients and in October 2008 for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex.
AstraZeneca stresses that the CRL does not alter in any way the current recommendations for the treatment of patients taking Seroquel XR or Seroquel for already approved indications in schizophrenia and bipolar disorder.
AstraZeneca, in a statement to investors, says it will report on progress when appropriate.
Source - AstraZeneca
Written by Christian Nordqvist
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/articles/134131.php>
APA
http://www.medicalnewstoday.com/articles/134131.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




